Zulilig Pharmas获得Bayer的Zam-Buk和Vapex品牌, Zuellig Pharma acquires Bayer’s Zam-Buk® and Vapex® brands for key Asian markets to expand consumer healthcare access.

Zulig Pharma从拜尔购买了Zam-Buk和Vapex的消费者医疗保健品牌,供泰国、新加坡、印度尼西亚、马来西亚和文莱市场使用。 Zuellig Pharma has acquired the Zam-Buk® and Vapex® consumer healthcare brands from Bayer for markets in Thailand, Singapore, Indonesia, Malaysia, and Brunei. 长期存在的品牌以减轻疼痛/疾病和拥堵闻名, 将扩大Zuellig在亚洲的消费者医疗保健存在。 The long-established brands, known for pain/itch relief and congestion relief, will expand Zuellig’s consumer healthcare presence in Asia. 该公司计划利用其区域网络提高可用性和可见度。 The company plans to use its regional network to boost availability and visibility. 购买支持Zuelig在18个经营市场改善医疗保健服务的战略。 The acquisition supports Zuellig’s strategy to improve healthcare access across its 18 operating markets.